Health and Fitness Health and Fitness
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ] - Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011
Tue, March 29, 2011
Mon, March 28, 2011
Sun, March 27, 2011
Fri, March 25, 2011
Thu, March 24, 2011
Wed, March 23, 2011
Tue, March 22, 2011
Mon, March 21, 2011
[ Mon, Mar 21st 2011 ] - Market Wire
30 p.m. ET
Sun, March 20, 2011
Fri, March 18, 2011
Thu, March 17, 2011
Wed, March 16, 2011
[ Wed, Mar 16th 2011 ] - Market Wire
30 p.m. Eastern Time

NuPathe to Present at the 10th Annual Needham Healthcare Conference


Published on 2011-03-29 05:45:33 - Market Wire
  Print publication without navigation


CONSHOHOCKEN, PA--(Marketwire - March 29, 2011) - NuPathe Inc. (NASDAQ: [ PATH ]), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that [ Jane Hollingsworth ], chief executive officer, will present a company overview at the 10th Annual Needham Healthcare Conference on Tuesday, April 5, 2011 at 2:40 p.m. EDT. The conference is being held at The New York Palace Hotel in New York, NY.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the call.

About NuPathe

NuPathe Inc. ([ www.nupathe.com ]) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, [ Zelrix ], is a single-use, transdermal sumatriptan patch being developed for the treatment of acute migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.


Publication Contributing Sources